Long-acting RNA interference therapy for hypertension could shift blood pressure control from daily pill-taking to scheduled, ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation.

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

The last time I wrote about Silence Therapeutics plc (SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

Delivering cutting-edge peer-reviewed research on using nucleic acids and related compounds to alter gene expression for therapeutic purposes. Sarah Allen, from the University of Massachusetts Chan ...

RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.